Skip to main content
. 2019 May 30;1(1):vdz007. doi: 10.1093/noajnl/vdz007

Fig. 2.

Fig. 2

Validated nomogram for predicted 12-, 18-, and 24-month survival for newly diagnosed isocitrate dehydrogenase-wild-type glioblastoma patients; the Ohio Brain Tumor Study, 2007–2017.